Tradestie Institutional Equity Comparison Engine

NVCT vs CGEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while NVCT counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, NVCT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, NVCT sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
NVCT N/M vs CGEN 12.4x Fwd P/E
Growth & Margin Winner CGEN
Op Margin 0.0% vs 41.3% ยท YoY +0.0% vs +102.1%
Momentum & Technical Winner NVCT
1Y +218.9% vs +23.2% ยท 52W Pos 57% vs 33%
Options & Structure Winner NVCT
BREAKDOWN (22nd %ile IV) vs BREAKDOWN (57th %ile IV)
NVCT NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.20
+0.47% 1D
Market Cap $657.2M
1M Return +1.37%
1Y Return +218.94%
Forward P/E N/M
Unified AI Score
53.4 / 100 HOLD
Tech 58.0 Fund 59.0 Flow 66.0 Mom 50.0
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
49.8 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 55.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NVCT +218.94% CGEN +23.17% Spread: +195.77 pp (NVCT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NVCT TTM Op. Margin: 0.0% CGEN TTM Op. Margin: 41.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVCT vs CGEN. Trailing 12-month operating profitability (NVCT 0.0% vs CGEN 41.3%) and valuation multiples (NVCT N/M vs CGEN 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NVCT (3) vs CGEN (7)
Institutional Metric NVCT CGEN Criterion Row Winner
Market Capitalization Scale $657.2M $193.2M Larger Scale NVCT
Trailing P/E Ratio Valuation N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio Valuation N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY) Growth +0.0% +102.1% Higher Growth CGEN
Operating Margin (TTM) Profitability 0.0% 41.3% Higher Margin CGEN
Net Profit Margin Profitability 0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency -67.0% 57.2% Higher ROE CGEN
52-Week Range Position Momentum 57% ($6โ€“$29) 33% ($1โ€“$3) Stronger Trend NVCT
Beta / 30D Volatility Risk Regime 0.70ฮฒ ยท 82% Vol 1.44ฮฒ ยท 62% Vol Lower Realized Risk CGEN
Unified Institutional Score Composite Signal 53.4 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite NVCT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NVCT vs CGEN Buy Guide
NVCT BREAKDOWN
99d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live NVCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NVCT nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.